Thus, this pathway may represent an axis for therapeutic intervention in obesity and related metabolic diseases, providing an approach to ensuring a durable response to β3-AR agonists in obesity treatment. Here, ADRB3 is linked to obesity due to melanocortin 4 receptor deficiency.